Member Info for jint

Note fund with changes:

NIHR155209 - A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) – Influenza (Anthony Gordon, Imperial College London)
Chair: Olivia Wu
Conflicts: None
Decision: Fund with Changes

https://www.nihr.ac.uk/documents/hta-funding-committee-public-minutes-flu-platform-study-rapid-call/31778

Excellent TommyD excellent!
Now we know the setup, lets hope Synairgen feel this PT is a suitable route for SNG001 to exploit the influenza angle/arrow!

Shocking that so many ppl were pressured with a threat on their careers and finances!

Manifesto, my guess would be to await the outcome for inclusion similar to ACTIV2 Phase2.

Forgot to include the Guidance Notes for 12/124 PT

https://www.google.co.uk/url?sa=t&source=web&cd=&ved=2ahUKEwiW7Nevrrz6AhXToVwKHe11AM8QFnoECAUQAQ&url=https%3A%2F%2Fwww.nihr.ac.uk%2Fdocuments%2Fguidance-notes-for-22124-a-platform-trial-to-evaluate-therapeutic-interventions-for-influenza%2F31287&usg=AOvVaw0K3iqkZyX7q2uJKSbSELo9

TommyD_19 / Size82
This is an informative link to the 22/124 PT:

https://www.google.co.uk/url?sa=t&source=web&cd=&ved=2ahUKEwiW7Nevrrz6AhXToVwKHe11AM8QFnoECAcQAQ&url=https%3A%2F%2Fwww.nihr.ac.uk%2Fdocuments%2F22124-a-platform-trial-to-evaluate-therapeutic-interventions-for-influenza-specification-document%2F31286&usg=AOvVaw1v0gD5wuliwpLgy9x8wo7q

In case anyone hasn’t seen it yet, was originally filed in the U.K. on 8th September 2020:

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022053792&_cid=P22-L7SSXV-82997-1

Tommy Claim 1 from the newly filed Covid patent application:

Claims:
1. Interferon-beta (IFN-b) for use in preventing or reducing the severity of lower respiratory tract illness in a patient infected with a coronavirus or other potentially pandemic-causing virus capable of causing acute respiratory distress syndrome (ARDS) and/or improving one or more symptoms and/or outcome in a patient so infected, wherein the interferon-beta is administered by inhalation.

ATB

Tommy I believe this may cover it, from filed Covid patent application:

Thus, the present invention provides IFN-b for use in preventing or reducing the severity of lower respiratory tract illness in a patient infected with a coronavirus capable of causing acute respiratory distress syndrome (ARDS), e.g. severe acute respiratory syndrome commensurate with categorisation as a SARS virus, and/or improving one or more symptoms and /or outcome in a patient so infected, wherein the IFN-b is administered by inhalation.

Ghia,
Your antics are indeed very subtle, very subtle!

The impact of mucormycosis (black fungus) on SARS-CoV-2-infected patients: at a glance

https://www.google.co.uk/url?sa=t&source=web&cd=&ved=2ahUKEwj7u7PZguj5AhUKiv0HHcSeCnwQFnoECAgQAQ&url=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs11356-022-22204-8&usg=AOvVaw0zG3dD2UC5UJx9iDkryssi

CDC Fungal diseases and Covid 19

https://www.google.co.uk/url?sa=t&source=web&cd=&ved=2ahUKEwi5nuzq_uf5AhWrS0EAHXhYDFsQFnoECAgQAQ&url=https%3A%2F%2Fwww.cdc.gov%2Ffungal%2Fcovid-fungal.html&usg=AOvVaw13BToRXYqfIcjFRSFhqrm3

Doc.Daneeka
Whilst imo STRIVE will go ahead and strongly believe SNG001 will be enrolled for Covid, I’m keeping an open mind to other possibilities following RM’s ‘many arrows in the air’ AGM comment and their interest in multi-viral platform trials.
That’s a sensible exploratory move seeing their original granted patent is for ILI (influenza like illness).

Doc.Daneeka
When the NIHR announced the pulling of funding and reclaiming left over funds from Recovery they may have had this in mind. They stated that they wanted an equitable system for choosing candidates for influenza trials, that appears fair enough to me.
Perhaps SNG001 may well get a look in.

https://www.google.co.uk/url?sa=t&source=web&cd=&ved=2ahUKEwi-y6LBrtj5AhXOQkEAHRypCb4QFnoECAoQAQ&url=https%3A%2F%2Fwww.nihr.ac.uk%2Ffunding%2F22124-a-platform-trial-to-evaluate-therapeutic-interventions-for-influenza%2F31293&usg=AOvVaw2m3_bx20jQAL_DeivNt_JF

https://www.google.co.uk/url?sa=t&source=web&cd=&ved=2ahUKEwjItKKTtNj5AhUOYcAKHW6ZA2IQFnoECAQQAQ&url=https%3A%2F%2Fwww.nihr.ac.uk%2Fdocuments%2Fguidance-notes-for-22124-a-platform-trial-to-evaluate-therapeutic-interventions-for-influenza%2F31287&usg=AOvVaw0K3iqkZyX7q2uJKSbSELo9

I’m not going to refute in anyway Wigster’s or Doc83 view of events, as their note taking in a difficult dynamic situation was commendable.

My version slightly (from memory) different (timing) but the aspect I was trying to get across was the ‘arrows or darts’ were not just being thrown/fired in wild abandonment.

ATB.

Doc.Daneeka
From memory I think it came towards the end of the AGM when wrapping up. It was preceded by Simon Shaw stating that “things were really beginning to hot up in the U.S.”

Perhaps Wigster or Doc83 can also corroborate.

ATB.

Regarding RM’s ‘darts’ comment at the AGM, he said “we have many darts in the air”.
The term ‘throwing’ never came into it.

Not wishing to appear pedantic but by adding ‘throwing’ into the mix, can be perceived as having a very different meaning.

My opinion at the time of the AGM was that they (SNG) had options/avenues in the fire that will/could be exploited.

ATB.

Publication 19th August 22

https://www.google.co.uk/url?sa=t&source=web&cd=&ved=2ahUKEwjw9fHu09P5AhXTa8AKHSg_AtEQFnoECDwQAQ&url=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41551-022-00925-y&usg=AOvVaw1o66a9_HjefqHXQRCcWNXh

Neutralizing IFN-a/? autoantibodies have been described in patients with severe COVID-19 disease and are presumed to be pathogenic.23 These likely pre-existing autoantibodies, which occur very rarely in the general population, block restriction of viral replication in cell culture and are thus likely to interfere with disease resolution. This discovery paved the way to identifying a subset of individuals at risk for life-threatening COVID-19 and proposed therapeutic use of IFN-ß in this population of patients.

and another:
https://www.google.co.uk/url?sa=t&source=web&cd=&ved=2ahUKEwit4fGg5dP5AhV-QEEAHXwGDZI4ChAWegQICRAB&url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS0092867422008510&usg=AOvVaw33ky86ZE0P88k2beccEW87

https://ars.els-cdn.com/content/image/1-s2.0-S0092867422008510-gr2.jpg

Hi Wigster77,
I confirm your take, my recollection from the AGM to the question regarding when was it expected that SNG001 would be in use, RM stated that they expected to be treating ppl over the winter period.
I took this to mean via a PT.

ATB